Stock & Company Details
CorMedix Inc $CRMD
Price:
N/A
N/A
78M
$571M
52 Week High:
N/A
10 Day Average Volume:
N/A
3.49
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
CRMD technical indicators
Latest CorMedix Inc (CRMD) indicator readings as of 2026-10-09.
CRMD's 14-day RSI is 39.2, in neutral territory. At $7.38 it is trading 6.5% below its 200-day moving average of $7.89, and below its 50-day average of $7.84. Price sits in the middle of its Bollinger Bands ($7.13 to $8.12). ADX reads 16.7, indicating a range-bound market rather than a trend.
Overview
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin™ is CE Marked and marketed in Europe and other territories as a medical device.
Finance Bot
Ask your questions
Start by typing a question below.
